Relationships between major epitopes of the IA-2 autoantigen in Type 1 diabetes: Implications for determinant spreading

Clinical Immunology

Volumn 160, Issue 2, 2015, Pages 226-236

  McLaughlin, Kerry A ^a   Richardson, Carolyn C ^a   Williams, Stefan ^a   Bonifacio, Ezio ^b   Morgan, Diana ^c   Feltbower, Richard G ^c   Powell, Michael ^d   Rees Smith, Bernard ^d   Furmaniak, Jadwiga ^d   Christie, Michael R ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d RSR LTD   (United Kingdom)

Author keywords

Autoantibody; Determinant spreading; Epitope; Monoclonal antibody; Type 1 diabetes

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; EPITOPE; IA 2 AUTOANTIGEN; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; ICA512 AUTOANTIBODY; PTPRN PROTEIN, HUMAN; RECEPTOR LIKE PROTEIN TYROSINE PHOSPHATASE;

ADOLESCENT; ADULT; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; BINDING AFFINITY; CHILD; COMPLEX FORMATION; DEGRADATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; JM DOMAIN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; PROTEIN TYROSINE PHOSPHATASE DOMAIN; SITE DIRECTED MUTAGENESIS; T LYMPHOCYTE; AMINO ACID SEQUENCE; IMMUNOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AMINO ACID SEQUENCE; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNITY; B-LYMPHOCYTES; CHILD; DIABETES MELLITUS, TYPE 1; EPITOPES; HUMANS; RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASES, CLASS 8; T-LYMPHOCYTES; YOUNG ADULT;

EID: 84938057757     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2015.06.002     Document Type: Article

References (38)

1. Weenink S.M., Christie M.R. Autoantibodies and autoimmunity: molecular mechanisms in health and disease. Autoantibodies in Diabetes 2005, 321-349. VCH Verlag GmbH & Co, Weinheim. M. Pollard (Ed.).
2. Ziegler A.G., Hummel M., Schenker M., Bonifacio E. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 1999, 48:460-468.
3. Brooks-Worrell B., Gersuk V.H., Greenbaum C., Palmer J.P. Intermolecular antigen spreading occurs during the preclinical period of human type 1 diabetes. J. Immunol. 2001, 166:5265-5270.
4. Barker J.M., Barriga K.J., Yu L., Miao D., Erlich H.A., Norris J.M., et al. Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). J. Clin. Endocrinol. Metab. 2004, 89:3896-3902.
5. Naserke H.E., Ziegler A.G., Lampasona V., Bonifacio E. Early development and spreading of autoantibodies to epitopes of IA-2 and their association with progression to type 1 diabetes. J. Immunol. 1998, 161:6963-6969.
6. Ziegler A.G., Rewers M., Simell O., Simell T., Lempainen J., Steck A., et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013, 309:2473-2479.
7. Dai Y.D., Carayanniotis G., Sercarz E. Antigen processing by autoreactive B cells promotes determinant spreading. Cell. Mol. Immunol. 2005, 2:169-175.
8. Silveira P.A., Grey S.T. B cells in the spotlight: innocent bystanders or major players in the pathogenesis of type 1 diabetes. Trends Endocrinol. Metab. 2006, 17:128-135.
9. Serreze D.V., Chapman H.D., Varnum D.S., Hanson M.S., Reifsnyder P.C., Richard S.D., et al. B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new "speed congenic" stock of NOD.Ig mu null mice. J. Exp. Med. 1996, 184:2049-2053.
10. Pescovitz M.D., Greenbaum C.J., Krause-Steinrauf H., Becker D.J., Gitelman S.E., Goland R., et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N. Engl. J. Med. 2009, 361:2143-2152.
11. Fenalti G., Hampe C.S., Arafat Y., Law R.H., Banga J.P., Mackay I.R., et al. COOH-terminal clustering of autoantibody and T-cell determinants on the structure of GAD65 provide insights into the molecular basis of autoreactivity. Diabetes 2008, 57:1293-1301.
12. Weenink S.M., Lo J., Stephenson C.R., McKinney P.A., Ananieva-Jordanova R., Rees Smith B., et al. Autoantibodies and associated T-cell responses to determinants within the 831-860 region of the autoantigen IA-2 in Type 1 diabetes. J. Autoimmun. 2009, 33:147-154.
13. McLaughlin K.A., Gulati K., Richardson C.C., Morgan D., Bodansky H.J., Feltbower R.G., et al. HLA-DR4-associated T and B cell responses to specific determinants on the IA-2 autoantigen in type 1 diabetes. J. Immunol. 2014, 193:4448-4456.
14. Simitsek P.D., Campbell D.G., Lanzavecchia A., Fairweather N., Watts C. Modulation of antigen processing by bound antibodies can boost or suppress class II major histocompatibility complex presentation of different T cell determinants. J. Exp. Med. 1995, 181:1957-1963.
15. Watts C., Antoniou A., Manoury B., Hewitt E.W., McKay L.M., Grayson L., et al. Modulation by epitope-specific antibodies of class II MHC-restricted presentation of the tetanus toxin antigen. Immunol. Rev. 1998, 164:11-16.
16. Christie M.R., Roll U., Payton M.A., Hatfield E.C., Ziegler A.G. Validity of screening for individuals at risk for type 1 diabetes by combined analysis of antibodies to recombinant proteins. Diabetes Care 1997, 20:965-970.
17. Christie M.R., Genovese S., Cassidy D., Bosi E., Brown T.J., Lai M., et al. Antibodies to islet 37k antigen, but not to glutamate decarboxylase, discriminate rapid progression to IDDM in endocrine autoimmunity. Diabetes 1994, 43:1254-1259.
18. Bearzatto M., Naserke H., Piquer S., Koczwara K., Lampasona V., Williams A., et al. Two distinctly HLA-associated contiguous linear epitopes uniquely expressed within the islet antigen 2 molecule are major autoantibody epitopes of the diabetes-specific tyrosine phosphatase-like protein autoantigens. J. Immunol. 2002, 168:4202-4208.
19. Lampasona V., Belloni C., Piquer S., Bonicchio S., Furlan R., Bonifacio E. Radiobinding assay for detecting autoantibodies to single epitopes. J. Immunol. Methods 2008, 336:127-134.
20. Dromey J.A., Weenink S.M., Peters G.H., Endl J., Tighe P.J., Todd I., et al. Mapping of epitopes for autoantibodies to the type 1 diabetes autoantigen IA-2 by peptide phage display and molecular modeling: overlap of antibody and T cell determinants. J. Immunol. 2004, 172:4084-4090.
21. Bearzatto M., Lampasona V., Belloni C., Bonifacio E. Fine mapping of diabetes-associated IA-2 specific autoantibodies. J. Autoimmun. 2003, 21:377-382.
22. Elvers K.T., Geoghegan I., Shoemark D.K., Lampasona V., Bingley P.J., Williams A.J. The core cysteines, (C909) of islet antigen-2 and (C945) of islet antigen-2beta, are crucial to autoantibody binding in type 1 diabetes. Diabetes 2013, 62:214-222.
23. Long A.E., Gillespie K.M., Rokni S., Bingley P.J., Williams A.J. Rising incidence of type 1 diabetes is associated with altered immunophenotype at diagnosis. Diabetes 2012, 61:683-686.
24. Ziegler A.G., Pflueger M., Winkler C., Achenbach P., Akolkar B., Krischer J.P., et al. Accelerated progression from islet autoimmunity to diabetes is causing the escalating incidence of type 1 diabetes in young children. J. Autoimmun. 2011, 37:3-7.
25. Bonifacio E., Lampasona V., Bingley P.J. IA-2 (islet cell antigen 512) is the primary target of humoral autoimmunity against type 1 diabetes-associated tyrosine phosphatase autoantigens. J. Immunol. 1998, 161:2648-2654.
26. Hatfield E.C., Hawkes C.J., Payton M.A., Christie M.R. Cross reactivity between IA-2 and phogrin/IA-2beta in binding of autoantibodies in IDDM. Diabetologia 1997, 40:1327-1333.
27. Piquer S., Valera L., Lampasona V., Jardin-Watelet B., Roche S., Granier C., et al. Monoclonal antibody 76F distinguishes IA-2 from IA-2beta and overlaps an autoantibody epitope. J. Autoimmun. 2006, 26:215-222.
28. Ananieva-Jordanova R., Evans M., Nakamatsu T., Premawardhana L.D., Sanders J., Powell M., et al. Isolation and characterisation of a human monoclonal autoantibody to the islet cell autoantigen IA-2. J. Autoimmun. 2005, 24:337-345.
29. Kolm-Litty V., Berlo S., Bonifacio E., Bearzatto M., Engel A.M., Christie M., et al. Human monoclonal antibodies isolated from type I diabetes patients define multiple epitopes in the protein tyrosine phosphatase-like IA-2 antigen. J. Immunol. 2000, 165:4676-4684.
30. Harlow E., Lane D. Antibodies:A Laboratory Manual 1988, Cold Spring Harbor Laboratory Press, New York.
31. Wenzlau J.M., Juhl K., Yu L., Moua O., Sarkar S.A., Gottlieb P., et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:17040-17045.
32. Kim C.S., Song M.K., Park J.S., Cho M.H., Kim H.J., Nam J.S., et al. The clinical and immunogenetic characteristics of adult-onset type 1 diabetes mellitus in Korea. Acta Diabetol. 2007, 44:45-54.
33. Sheshberadaran H., Payne L.G. Protein antigen-monoclonal antibody contact sites investigated by limited proteolysis of monoclonal antibody-bound antigen: protein "footprinting". Proc. Natl. Acad. Sci. U. S. A. 1988, 85:1-5.
34. Bingley P.J., Bonifacio E., Gale E.A. Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus. Lancet 1994, 344:266-267.
35. Noorchashm H., Lieu Y.K., Noorchashm N., Rostami S.Y., Greeley S.A., Schlachterman A., et al. I-Ag7-mediated antigen presentation by B lymphocytes is critical in overcoming a checkpoint in T cell tolerance to islet beta cells of nonobese diabetic mice. J. Immunol. 1999, 163:743-750.
36. Arif S., Tree T.I., Astill T.P., Tremble J.M., Bishop A.J., Dayan C.M., et al. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J. Clin. Invest. 2004, 113:451-463.
37. Lampasona V., Bearzatto M., Genovese S., Bosi E., Ferrari M., Bonifacio E. Autoantibodies in insulin-dependent diabetes recognize distinct cytoplasmic domains of the protein tyrosine phosphatase-like IA-2 autoantigen. J. Immunol. 1996, 157:2707-2711.
38. Piquer S., Belloni C., Lampasona V., Bazzigaluppi E., Vianello M., Giometto B., et al. Humoral autoimmune responses to glutamic acid decarboxylase have similar target epitopes and subclass that show titer-dependent disease association. Clin. Immunol. 2005, 117:31-35.